Smith & Nephew stock rises on earnings context and investor focus
Published on 07/22/2026 at 03:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Smith & Nephew (ISIN GB0009223206) is trading against a backdrop of 2025 revenue of $5.83 billion, adjusted trading profit of $1.04 billion, and trading profit margin of 17.9% in its latest annual results. The company also reported 2025 underlying revenue growth of 7.6%, a set of numbers that keeps the London-listed medtech name in a reporting-driven phase.
2025 revenue at $5.83 billion
The latest annual figure gives investors a clear reference point: revenue rose to $5.83 billion in 2025, up 7.6% on an underlying basis. Trading profit reached $1.04 billion and the margin was 17.9%, a combination that highlights how closely the shares now track execution rather than broad sector sentiment.
Smith & Nephew's investor relations materials remain the main source for those figures, and the latest published report is the best anchor for the stock until the next update arrives. For a company with a large reconstructive and sports medicine footprint, margin progress matters because it filters directly into earnings quality.
Margin of 17.9%
The 17.9% trading profit margin in 2025 is worth watching because it can be compared with revenue growth of 7.6% in the same year. That gap shows the business did not just grow by volume; it also converted part of that growth into operating leverage.
The same report also showed trading profit of $1.04 billion, which gives a second concrete profit marker for valuation work. Those figures are more useful for the stock than a generic business description because they frame how much room the company has to absorb pricing pressure, mix shifts, or slower hospital demand.
Smith & Nephew annual results and investor materials
The latest annual report and investor pages provide the 2025 revenue, profit, and margin figures used in this article, together with the companys own presentation of the business mix.
Sports medicine matters
One representative product area is sports medicine, which sits alongside reconstructive surgery and advanced wound management in the group portfolio. That mix is relevant because revenue momentum in 2025 did not come from a single line; it reflected the broader commercial base of the company.
The stock case therefore rests on a simple question: can Smith & Nephew keep turning that 2025 pattern into steadier profit conversion in future periods? The reported 7.6% underlying revenue growth and 17.9% margin give investors the baseline they need to judge the next update.
London listing context
Smith & Nephew stock is tied to the London market, and the share price reference point is the next item that usually matters most for short-term trading decisions. When a current quote is available, it should be read alongside the 2025 revenue of $5.83 billion, trading profit of $1.04 billion, and margin of 17.9% rather than in isolation.
Fact box and market context below keep the valuation lens anchored to the companys own reporting cycle and its UK listing.
Company details
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- Ticker: LSE: SN
- Trading venue: London Stock Exchange
- Sector / Industry: Health Care, Medical Devices
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
